[1] |
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8: 315-317.
|
[2] |
Lai P, Weng J, Guo L, et al. Novel insights into MSC-EVs therapy for immune diseases[J]. Biomark Res, 2019,7:6. doi: 10.1186/s40364-019-0156-0.
|
[3] |
Zhu R, Yan T, Feng Y, et al. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms[J]. Cell Res, 2021, 31: 1244-1262.
|
[4] |
Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases[J]. Nat Rev Nephrol, 2018, 14: 493-507.
|
[5] |
Dhingra S, Li P, Huang XP, et al. Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function[J]. Circulation, 2013, 128: S69-S78.
|
[6] |
Wang Y, Chen X, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications[J]. Nature Immunology, 2014, 15: 1009-1016.
|
[7] |
Sadik A, Somarribas PL, Ozturk S, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression[J]. Cell, 2020, 182: 1252-1270.
|
[8] |
Rothhammer V, Quintana FJ. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease[J]. Nat Rev Immunol, 2019, 19: 184-197.
|
[9] |
Gutierrez-Vazquez C, Quintana FJ. Regulation of the immune response by the aryl hydrocarbon receptor[J]. Immunity, 2018, 48: 19-33.
|
[10] |
Xu Q, Wang L, Li H, et al. Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-beta[J]. Int J Oncol, 2012, 41: 959-968.
|
[11] |
Zhu W, Yuan Y, Liao G, et al. Mesenchymal stem cells ameliorate hyperglycemia-induced endothelial injury through modulation of mitophagy[J]. Cell Death Dis, 2018. doi: 10.1038/s41419-018-0861-x.
|
[12] |
Deng L, Li H, Su X, et al. Chlorzoxazone, a small molecule drug, augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation[J]. Cell Death Dis, 2020,11:158. doi: 10.1038/s41419-020-2357-8.
|
[13] |
Renesme L, Pierro M, Cobey KD, et al. Definition and characteristics of mesenchymal stromal cells in preclinical and clinical studies: a scoping review[J]. Stem Cells Transl Med, 2022, 11: 44-54.
|
[14] |
Zhang C, Zhou L, Wang Z, et al. Eradication of specific donor-dependent variations of mesenchymal stem cells in immunomodulation to enhance therapeutic values[J]. Cell Death Dis, 2021,12:357. doi: 10.1038/s41419-021-03644-5.
|
[15] |
Yao M, Cui B, Zhang W, et al. Exosomal miR-21 secreted by IL-1beta-primed-mesenchymal stem cells induces macrophage M2 polarization and ameliorates sepsis[J]. Life Sci, 2021,264:118658. doi: 10.1016/j.lfs.2020.118658.
|